Premium
A dose response of dietary resistant starch in human subjects using yogurt as the vehicle for delivery
Author(s) -
Keenan Michael J.,
Aryana Kayanush J.,
LammiKeefe Carol,
Finley John,
Shen Li,
Raggio Anne M.,
Zhou June,
McCutcheon Kathleen L.,
Goita M'Famara,
Lam Nguyen,
Martin Roy J.
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.438.7
This human study follows our successful use of animal models on mechanisms of health benefits of dietary RS. Studies showed increased insulin sensitivity; consistently elevated GLP‐1; GLP‐1 gene expression elevated in gut; GLP‐1 receptor required for RS to induce fat loss; fat oxidation increased; enhanced expression of cecal cell genes associated with gut health; and a dramatic alteration of the microbiota, especially bacteria that produce butyrate. The purpose of this pilot dose response study is to determine the dose of RS necessary to produce similar fermentation and endocrine changes seen in animals. RS as part of high‐amylose cornstarch (Hi‐Maize®260) or control starch (Amioca®) was given in yogurt. Taste tests showed high acceptability. Yogurt also contained skim milk, nonfat dry milk and blueberry or strawberry puree. Adults were fed increasing doses of 0, 25 and 50g RS per day at two week intervals; all completed the study. We identified responders as those that showed an elevation of serum active GLP‐1 (ALPCO). Ten subjects had GLP‐1 measured for 0 g RS and 50 g RS 30 min after consumption of yogurt. Six of 10 subjects showed increased serum active GLP‐1, but four subjects did not show this response to the RS. This study showed 50g of RS in yogurt is tolerated and may be a useful approach for more detailed clinical evaluation of health benefits and mechanisms of action. Funding: National Starch, LSU AgCenter.